Europe artificial intelligence (AI) in drug discovery market reached $108.6 million in 2019 and will grow by 28.7% over 2020-2026 owing to the rising need for AI technology in drug discovery and development.
Highlighted with 37 tables and 54 figures, this 123-page report “Europe Artificial Intelligence (AI) in Drug Discovery Market 2020-2026 by Offering, Technology, Drug Type, Therapeutic Area, Application, End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe AI in drug discovery market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report provides historical market data for 2015-2019, revenue estimates for 2020, and forecasts from 2021 till 2026. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe AI in drug discovery market in every aspect of the classification from perspectives of Offering, Technology, Drug Type, Therapeutic Area, Application, End User, and Country.
Based on offering, the Europe market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section.
• Software
• Service
Based on technology, the Europe market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section.
• Deep Learning
• Supervised Learning
• Reinforcement Learning
• Unsupervised Learning
• Other Technologies
Based on drug type, the Europe market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section.
• Large-molecule Drugs
• Small-molecular Drugs
Based on therapeutic area, the Europe market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section.
• Oncology
• Neurodegenerative Diseases
• Cardiovascular Disease
• Metabolic Diseases
• Other Therapeutic Areas
Based on application, the Europe market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section.
• Information & Data Analysis
• Drug Design
• Drug Evaluation
• Clinical Trials
• Other Applications
Based on end user, the Europe market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section.
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Contract Research Organizations
Geographically, the following national/local markets are fully investigated:
• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe (further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)
For each of the aforementioned countries, detailed analysis and data for annual revenue are available for 2015-2026. The breakdown of key national markets by Technology, Therapeutic Area, and End User over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Europe AI in drug discovery market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
Atomwise, Inc.
BenevolentAI
Berg LLC
Bioage
BIOAGE
Cloud Pharmaceuticals, Inc.
Cyclica
Deep Genomics
Envisagenics
Exscientia
Google
IBM Corporation
Insilico Medicine
Microsoft Corporation
Numedii, Inc.
Numerate
NVIDIA Corporation
Owkin, Inc.
Twoxar, Incorporated
Verge Genomics
Xtalpi, Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Market Research Methodology 11
1.2.2 Market Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 14
1.2.6 Market Size/Share Estimation 15
1.2.7 Research Limitations 16
1.3 Executive Summary 17
2 Market Overview and Dynamics 20
2.1 Market Size and Forecast 20
2.2 Major Growth Drivers 22
2.3 Market Restraints and Challenges 25
2.4 Emerging Opportunities and Market Trends 28
2.5 Porter’s Fiver Forces Analysis 32
3 Segmentation of Europe Market by Offering 36
3.1 Market Overview by Offering 36
3.2 Software 38
3.3 Service 39
4 Segmentation of Europe Market by Technology 40
4.1 Market Overview by Technology 40
4.2 Deep Learning 42
4.3 Supervised Learning 43
4.4 Reinforcement Learning 44
4.5 Unsupervised Learning 45
4.6 Other Technologies 46
5 Segmentation of Europe Market by Drug Type 47
5.1 Market Overview by Drug Type 47
5.2 Large-molecule Drugs 49
5.3 Small-molecular Drugs 50
6 Segmentation of Europe Market by Therapeutic Area 51
6.1 Market Overview by Therapeutic Area 51
6.2 Oncology 54
6.3 Neurodegenerative Diseases 55
6.4 Cardiovascular Disease 56
6.5 Metabolic Diseases 57
6.6 Other Therapeutic Areas 58
7 Segmentation of Europe Market by Application 59
7.1 Market Overview by Application 59
7.2 Information & Data Analysis 61
7.3 Drug Design 62
7.4 Drug Evaluation 63
7.5 Clinical Trials 64
7.6 Other Applications 65
8 Segmentation of Europe Market by End User 66
8.1 Market Overview by End User 66
8.2 Pharmaceutical & Biotechnology Companies 68
8.3 Academic & Research Institutes 69
8.4 Contract Research Organizations 70
9 European Market 2019-2026 by Country 71
9.1 Overview of European Market 71
9.2 UK 75
9.3 France 77
9.4 Germany 79
9.5 Spain 81
9.6 Italy 83
9.7 Russia 85
9.8 Rest of European Market 87
10 Competitive Landscape 89
10.1 Overview of Key Vendors 89
10.2 New Product Launch, Partnership, Investment, and M&A 94
10.3 Company Profiles 95
Atomwise, Inc. 95
BenevolentAI 97
Berg LLC 98
Bioage 99
BIOAGE 100
Cloud Pharmaceuticals, Inc. 101
Cyclica 102
Deep Genomics 103
Envisagenics 104
Exscientia 105
Google 106
IBM Corporation 107
Insilico Medicine 108
Microsoft Corporation 109
Numedii, Inc. 110
Numerate 111
NVIDIA Corporation 112
Owkin, Inc. 113
Twoxar, Incorporated 114
Verge Genomics 115
Xtalpi, Inc. 116
11 Investing in Europe Market: Risk Assessment and Management 117
11.1 Risk Evaluation of Europe Market 117
11.2 Critical Success Factors (CSFs) 120
Related Reports and Products 123
Table 1. Snapshot of Europe AI in Drug Discovery Market, 2019-2026 18
Table 2. Main Product Trends and Market Opportunities in Europe AI in Drug Discovery Market 28
Table 3. Europe AI in Drug Discovery Market by Offering, 2015-2026, $ mn 36
Table 4. Europe AI in Drug Discovery Market by Technology, 2015-2026, $ mn 40
Table 5. Europe AI in Drug Discovery Market by Drug Type, 2015-2026, $ mn 47
Table 6. Europe AI in Drug Discovery Market by Therapeutic Area, 2015-2026, $ mn 51
Table 7. Selected Drug Development Pipelines Aided by AI 53
Table 8. Europe AI in Drug Discovery Market by Application, 2015-2026, $ mn 59
Table 9. Europe AI in Drug Discovery Market by End User, 2015-2026, $ mn 66
Table 10. Europe AI in Drug Discovery Market by Country, 2015-2026, $ mn 73
Table 11. UK AI in Drug Discovery Market by Technology, 2015-2026, $ mn 76
Table 12. UK AI in Drug Discovery Market by Therapeutic Area, 2015-2026, $ mn 76
Table 13. UK AI in Drug Discovery Market by End User, 2015-2026, $ mn 76
Table 14. France AI in Drug Discovery Market by Technology, 2015-2026, $ mn 78
Table 15. France AI in Drug Discovery Market by Therapeutic Area, 2015-2026, $ mn 78
Table 16. France AI in Drug Discovery Market by End User, 2015-2026, $ mn 78
Table 17. Germany AI in Drug Discovery Market by Technology, 2015-2026, $ mn 80
Table 18. Germany AI in Drug Discovery Market by Therapeutic Area, 2015-2026, $ mn 80
Table 19. Germany AI in Drug Discovery Market by End User, 2015-2026, $ mn 80
Table 20. Spain AI in Drug Discovery Market by Technology, 2015-2026, $ mn 82
Table 21. Spain AI in Drug Discovery Market by Therapeutic Area, 2015-2026, $ mn 82
Table 22. Spain AI in Drug Discovery Market by End User, 2015-2026, $ mn 82
Table 23. Italy AI in Drug Discovery Market by Technology, 2015-2026, $ mn 84
Table 24. Italy AI in Drug Discovery Market by Therapeutic Area, 2015-2026, $ mn 84
Table 25. Italy AI in Drug Discovery Market by End User, 2015-2026, $ mn 84
Table 26. Russia AI in Drug Discovery Market by Technology, 2015-2026, $ mn 86
Table 27. Russia AI in Drug Discovery Market by Therapeutic Area, 2015-2026, $ mn 86
Table 28. Russia AI in Drug Discovery Market by End User, 2015-2026, $ mn 86
Table 29. AI in Drug Discovery Market in Rest of Europe by Country, 2015-2026, $ mn 88
Table 30. Use Cases of AI for Drug Discovery by Selected Pharmaceutical Companies 92
Table 31. Atomwise, Inc.: Company Snapshot 95
Table 32. Atomwise, Inc.: Business Segmentation 95
Table 33. Atomwise, Inc.: Product Portfolio 96
Table 34. Atomwise, Inc.: Revenue, 2016-2018, $ mn 96
Table 35. Atomwise, Inc.: Recent Developments 96
Table 36. Risk Evaluation for Investing in Europe Market, 2019-2026 118
Table 37. Critical Success Factors and Key Takeaways 121
